1. Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro.
- Author
-
Eke I, Ingargiola M, Förster C, Kunz-Schughart LA, Baumann M, Runge R, Freudenberg R, Kotzerke J, Heldt JM, Pietzsch HJ, Steinbach J, and Cordes N
- Subjects
- Cell Count, Cell Line, Tumor, Cell Survival drug effects, Cell Survival radiation effects, Cetuximab, Combined Modality Therapy, DNA Breaks, Double-Stranded drug effects, DNA Breaks, Double-Stranded radiation effects, ErbB Receptors metabolism, Gene Expression Regulation, Neoplastic drug effects, Gene Expression Regulation, Neoplastic radiation effects, Humans, Intracellular Space drug effects, Intracellular Space metabolism, Intracellular Space radiation effects, Molecular Targeted Therapy, Pentetic Acid chemistry, Phosphorylation drug effects, Phosphorylation radiation effects, Protein Transport drug effects, Protein Transport radiation effects, Signal Transduction drug effects, Signal Transduction radiation effects, Yttrium Radioisotopes chemistry, Yttrium Radioisotopes therapeutic use, Antibodies, Monoclonal, Humanized chemistry, Antibodies, Monoclonal, Humanized pharmacology, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacology, Head and Neck Neoplasms pathology
- Abstract
Purpose: Epidermal growth factor receptor (EGFR) is critically involved in progression and therapy resistance of squamous cell carcinoma (SCC). Albeit EGFR targeting could improve the effect of radiotherapy on patients' outcome, the clinical results failed to meet expectations from preclinical studies. In this work, we evaluated the potential of the radionuclide Yttrium-90 ((90)Y) bound to Cetuximab ((90)Y-Cetuximab) as novel targeting approach for SCC cells in vitro., Materials and Methods: FaDu and A431 cell lines were used. EGFR subcellular localization, clonogenic survival, radiation-induced γH2AX foci and EGFR signaling were examined. Cells were treated with DTPA, DTPA-Cetuximab, (90)Y and (90)Y-Cetuximab alone or in combination with external X-ray irradiation., Results: Dose- and cell line-dependently, (90)Y-Cetuximab mediated a significant reduction in clonogenicity relative to unbound (90)Y. Combined 2-Gy external radiation plus 2-Gy equivalent dose of (90)Y-Cetuximab was more effective than equivalent doses of (90)Y and X-ray radiation. Analogous effects were observed in the number of residual radiation-induced foci. Additionally, EGFR, ERK1/2 and AKT phosphorylation showed alterations upon different treatments., Conclusions: Our findings show that Cetuximab-conjugated (90)Y has a significant potential to eradicate human SCC cells. A combination of radioimmunotherapeutic compounds and external radiotherapy might be a promising treatment strategy for clinical application. more...
- Published
- 2014
- Full Text
- View/download PDF